Literature DB >> 1684547

Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.

D M Yurek1, K Steece-Collier, T J Collier, J R Sladek.   

Abstract

The effect of chronic levodopa treatment on the function of embryonic mesencephalic tissue grafts was assessed in rats by monitoring rotational behavior elicited by dopamine (DA) agonists before and after neural grafting. Rats were given unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal pathway and baseline measures of rotational behavior induced by D1 receptor stimulation, D2 receptor stimulation, or amphetamine were determined. Subsequently, DA grafts were implanted into the lesioned striatum and chronic regimens of either saline or levodopa began one day after neural grafting and were continued for 7 weeks. Rotational behavior elicited by the D1 agonist, SKF 38393, was completely attenuated throughout the six-week-period following the commencement of levodopa treatment, regardless of the absence or presence of a DA graft. Conversely, rotational behavior elicited by the D2 agonist, quinpirole, was significantly elevated in ungrafted animals receiving chronic levodopa. Grafted animals receiving chronic levodopa did not show a significant reduction in rotational behavior, whereas grafted animals receiving chronic saline showed a significant 67% reduction in quinpirole-induced rotational behavior. Amphetamine-induced rotational behavior was reduced in both levodopa and saline treated grafted animals, however grafted animals receiving chronic levodopa treatment showed a reduction of rotational behavior that was uncharacteristic and less compensatory than that observed in grafted animals receiving chronic saline treatment. Morphology of grafts indicate that there were areas of impaired neurite outgrowth of TH-positive fibers in animals treated with levodopa. The results of the present study suggest that the impaired recovery in quinpirole- and amphetamine-induced rotational behavior in grafted animals receiving chronic levodopa treatment may be related to (1) impaired graft function, (2) an alteration in pre- and postsynaptic mechanisms in the host DAergic system, or (3) a combined effect of (1) and (2).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684547     DOI: 10.1007/bf00231044

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  40 in total

1.  Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.

Authors:  T M Engber; Z Susel; J L Juncos; T N Chase
Journal:  Eur J Pharmacol       Date:  1989-09-22       Impact factor: 4.432

2.  D1-type dopamine receptors inhibit growth cone motility in cultured retina neurons: evidence that neurotransmitters act as morphogenic growth regulators in the developing central nervous system.

Authors:  K L Lankford; F G DeMello; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system.

Authors:  J Scheel-Krüger
Journal:  Acta Neurol Scand Suppl       Date:  1986

4.  Studies on the mechanism of the L-3,4-dihydroxyphenylalanine-induced decrease in tyrosine hydroxylase activity.

Authors:  W Dairman; S Udenfriend
Journal:  Mol Pharmacol       Date:  1972-05       Impact factor: 4.436

5.  In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-DOPA.

Authors:  F Ponzio; M Cimino; G Achilli; M Lipartiti; C Perego; G Vantini; S Algeri
Journal:  Life Sci       Date:  1984-05-28       Impact factor: 5.037

Review 6.  On the mechanism of the antiparkinsonian action of 1-DOPA and bromocriptine: a theoretical and experimental analysis of dopamine receptor sub- and supersensitivity.

Authors:  L F Agnati; K Fuxe
Journal:  J Neural Transm Suppl       Date:  1980

Review 7.  Dopamine cell replacement: Parkinson's disease.

Authors:  D M Yurek; J R Sladek
Journal:  Annu Rev Neurosci       Date:  1990       Impact factor: 12.449

8.  Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics.

Authors:  P Muller; P Seeman
Journal:  Eur J Pharmacol       Date:  1979-04-15       Impact factor: 4.432

9.  Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.

Authors:  H S Pan; J B Penney; A B Young
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

10.  Behavioural and biochemical changes following chronic administration of L-dopa to rats.

Authors:  C Pycock; D Dawbarn; C O'Shaughnessy
Journal:  Eur J Pharmacol       Date:  1982-04-23       Impact factor: 4.432

View more
  7 in total

1.  Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms.

Authors:  M A Mena; M J Casarejos; A Carazo; C L Paíno; J García de Yébenes
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

3.  Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic grafts.

Authors:  F L Van Muiswinkel; J G Bol; J M Ruijter; J C Stoof; B Drukarch; H W Steinbusch
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

Review 4.  Cell-based therapies for Parkinson's disease: past, present, and future.

Authors:  Kathleen M Fitzpatrick; James Raschke; Marina E Emborg
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 5.  Fetal tissue transplantation for patients with Parkinson's disease: a database of published clinical results.

Authors:  E D Clarkson
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

6.  Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.

Authors:  Ludivine S Breger; Korbinian Kienle; Gaynor A Smith; Stephen B Dunnett; Emma L Lane
Journal:  Brain Behav Immun       Date:  2016-11-15       Impact factor: 7.217

7.  Defining the unknowns for cell therapies in Parkinson's disease.

Authors:  Emma L Lane; Mariah J Lelos
Journal:  Dis Model Mech       Date:  2022-09-27       Impact factor: 5.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.